Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer
- 8 April 2011
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 25 (7) , 2433-2446
Abstract
Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)‐status in breast cancer patients is possible via noninvasive imaging, provided adequate tracers are used. In this study, we describe the generation of a panel of 38 nanobodies, small HER2‐binding fragments that are derived from heavy‐chain‐only antibodies raised in an immunized dromedary. In search of a lead compound, a subset of nanobodies was biochemically characterized in depth and preclinically tested for use as tracers for imaging of xenografted tumors. The selected compound, 2Rs15d, was found to be stable and to interact specifically with HER2 recombinant protein and HER2‐expressing cells in ELISA, surface plasmon resonance, flow cytometry, and radioligand binding studies with low nanomolar affinities, and did not compete with anti‐HER2 therapeutic antibodies trastuzumab and pertuzumab. Single‐photon‐emission computed tomography (SPECT) imaging quantification and biodistribution analyses showed that 99m Tc‐labeled 2Rs15d has a high tumor uptake in 2 HER2 + tumor models, fast blood clearance, low accumulation in nontarget organs except kidneys, and high concomitant tumor‐to‐blood and tumor‐to‐muscle ratios at 1 h after intravenous injection. These values were dramatically lower for an irrelevant control 99m Tc‐nanobody and for 99m Tc‐2Rs15d targeting a HER2 – tumor.—Vaneycken, I., Devoogdt, N., Van Gassen, N., Vincke, C., Xavier, C., Wernery, U., Muyldermans, S., Lahoutte, T., Caveliers, V. Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 25, 2433–2446 (2011). www.fasebj.orgKeywords
This publication has 30 references indexed in Scilit:
- Localization, mechanism and reduction of renal retention of technetium‐99m labeled epidermal growth factor receptor‐specific nanobody in miceContrast Media & Molecular Imaging, 2010
- General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody ScaffoldJournal of Biological Chemistry, 2009
- SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR ExpressionMolecular Imaging and Biology, 2008
- From Bench to Bedside with Targeted Therapies2008
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Selection and Characterization of Her2 Binding-designed Ankyrin Repeat ProteinsJournal of Biological Chemistry, 2006
- Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain AntibodiesJournal of Molecular Biology, 2005
- Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic diseaseBritish Journal of Cancer, 2005
- Selection and identification of single domain antibody fragments from camel heavy‐chain antibodiesFEBS Letters, 1997
- Naturally occurring antibodies devoid of light chainsNature, 1993